Regulatory effects of SKAR in interferon α signaling and its role in the generation of type I IFN responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 31, 2014, Pages 11377-11382

  Kroczynska, Barbara ^a   Mehrotra, Swarna ^a   Majchrzak Kita, Beata ^b,c   Arslan, Ahmet Dirim ^a   Altman, Jessica K ^a,d   Stein, Brady L ^a   McMahon, Brandon ^a   Kozlowski, Piotr ^e   Kahle, Philipp J ^f   Eklund, Elizabeth A ^a,d   Fish, Eleanor N ^b,c   Platanias, Leonidas C ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF WARSAW   (Poland)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 1; INITIATION FACTOR 4G; INTERFERON STIMULATED GENE 15; MESSENGER RNA; RNA BINDING PROTEIN; S6 KINASE; S6 KINASE 1 ALY REF LIKE TARGET PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INTERFERON INDUCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; GUANOSINE; HUMANS; INTERFERON-ALPHA; MICE; NUCLEAR CAP-BINDING PROTEIN COMPLEX; NUCLEAR PROTEINS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; UBIQUITINS;

EID: 84905668784     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405250111     Document Type: Article

References (49)

1. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227-264. (Pubitemid 28411130)
2. Borden EC, et al. (2007) Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990. (Pubitemid 350201788)
3. Donnelly RP, Kotenko SV (2010) Interferon-λ: A new addition to an old family. J Interferon Cytokine Res 30(8):555-564.
4. González-Navajas JM, Lee J, David M, Raz E (2012) Immunomodulatory functions of type I interferons. Nat Rev Immunol 12(2):125-135.
5. Hall JC, Rosen A (2010) Type I interferons: Crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 6(1):40-49.
6. Platanias LC (2013) Interferons and their antitumor properties. J Interferon Cytokine Res 33(4):143-144.
7. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135(1):44- 53.
8. Stauffer Larsen T, et al. (2013) Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 37(9):1041-1045.
9. Killestein J, Polman CH (2011) Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 7(4):221-228.
10. Kaufman HL, et al. (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10(10):588-598.
11. Wahren-Herlenius M, Dörner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382(9894):819-831.
12. Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 13(6):249.
13. Young NS, Calado RT, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108(8):2509-2519.
14. Darnell JE, Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415-1421. (Pubitemid 24217131)
15. Levy DE, Darnell JE, Jr (2002) Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651-662. (Pubitemid 34987786)
16. Stark GR, Darnell JE, Jr (2012) The JAK-STAT pathway at twenty. Immunity 36(4):503-514.
17. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375-386.
18. Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101(12):4667-4679.
19. Uddin S, et al. (1999) Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 274(42):30127-30131.
20. Joshi S, et al. (2009) Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci USA 106(29):12097-12102.
21. Mehrotra S, et al. (2013) Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem 288(33):23814-23822.
22. Beauchamp EM, Platanias LC (2013) The evolution of the TOR pathway and its role in cancer. Oncogene 32(34):3923-3932.
23. Kaur S, et al. (2007) Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 282(3):1757-1768. (Pubitemid 47076718)
24. Kaur S, et al. (2008) Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol 181(10):7316-7323.
25. Kaur S, et al. (2008) Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci USA 105(12):4808-4813. (Pubitemid 351753828)
26. Kaur S, et al. (2012) Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci USA 109(20):7723-7728.
27. Richardson CJ, et al. (2004) SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 14(17):1540-1549. (Pubitemid 39290051)
28. Ma XM, Yoon SO, Richardson CJ, Jülich K, Blenis J (2008) SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 133(2):303-313. (Pubitemid 351508301)
29. McKendrick L, Thompson E, Ferreira J, Morley SJ, Lewis JD (2001) Interaction of eukaryotic translation initiation factor 4G with the nuclear cap-binding complex provides a link between nuclear and cytoplasmic functions of the m(7) guanosine cap. Mol Cell Biol 21(11):3632-3641. (Pubitemid 32466977)
30. Lejeune F, Ranganathan AC, Maquat LE (2004) eIF4G is required for the pioneer round of translation in mammalian cells. Nat Struct Mol Biol 11(10):992-1000. (Pubitemid 39315304)
31. Fortes P, et al. (2000) The yeast nuclear cap binding complex can interact with translation factor eIF4G and mediate translation initiation. Mol Cell 6(1):191-196.
32. Kroczynska B, et al. (2009) Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol 29(10):2865-2875.
33. Kroczynska B, Sharma B, Eklund EA, Fish EN, Platanias LC (2012) Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. Mol Cell Biol 32(14):2809-2822.
34. Choe J, et al. (2012) Translation initiation on mRNAs bound by nuclear cap-binding protein complex CBP80/20 requires interaction between CBP80/20-dependent translation initiation factor and eukaryotic translation initiation factor 3g. J Biol Chem 287(22):18500-18509.
35. Izaurralde E, et al. (1994) A nuclear cap binding protein complex involved in premRNA splicing. Cell 78(4):657-668. (Pubitemid 24268588)
36. Wilson KF, Wu WJ, Cerione RA (2000) Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex. J Biol Chem 275(48):37307-37310. (Pubitemid 32007059)
37. Calero G, et al. (2002) Structural basis of m7GpppG binding to the nuclear cap-binding protein complex. Nat Struct Biol 9(12):912-917. (Pubitemid 35417059)
38. Kroczynska B, et al. (2011) Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλsignaling. J Biol Chem 286(2):1147- 1156.
39. Holz MK, Ballif BA, Gygi SP, Blenis J (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123(4):569-580. (Pubitemid 41608461)
40. Shveygert M, Kaiser C, Bradrick SS, Gromeier M (2010) Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol Cell Biol 30(21):5160-5167.
41. Chiu SY, Lejeune F, Ranganathan AC, Maquat LE (2004) The pioneer translation initiation complex is functionally distinct from but structurally overlaps with the steadystate translation initiation complex. Genes Dev 18(7):745-754. (Pubitemid 38480887)
42. Lejeune F, Ishigaki Y, Li X, Maquat LE (2002) The exon junction complex is detected on CBP80-bound but not eIF4E-bound mRNA in mammalian cells: Dynamics of mRNP remodeling. EMBO J 21(13):3536-3545. (Pubitemid 34760583)
43. Le Hir H, Séraphin B (2008) EJCs at the heart of translational control. Cell 133(2):213-216. (Pubitemid 351508309)
44. Maquat LE, Carmichael GG (2001) Quality control of mRNA function. Cell 104(2):173-176. (Pubitemid 32174833)
45. Nott A, Le Hir H, Moore MJ (2004) Splicing enhances translation in mammalian cells: An additional function of the exon junction complex. Genes Dev 18(2):210-222. (Pubitemid 38141788)
46. Ishigaki Y, Li X, Serin G, Maquat LE (2001) Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 106(5):607-617. (Pubitemid 32879322)
47. Fiesel FC, Weber SS, Supper J, Zell A, Kahle PJ (2012) TDP-43 regulates global translational yield by splicing of exon junction complex component SKAR. Nucleic Acids Res 40(6):2668-2682.
48. Smyk A, Szuminska M, Uniewicz KA, Graves LM, Kozlowski P (2006) Human enhancer of rudimentary is a molecular partner of PDIP46/SKAR, a protein interacting with DNA polymerase delta and S6K1 and regulating cell growth. FEBS J 273(20):4728-4741. (Pubitemid 44508593)
49. Sharma B, et al. (2012) Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem 287(50):42352-42360.